Uli Hacksell has over 20 years of international management experience from both large pharmaceutical and biotech companies. He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ.

Uli Hacksell. Born: 1950 Title: Member of the Board since 2018. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its

Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 6 maj 2020, kl 08.30. Uli Alf Hacksell is President, Chief Executive Officer & Director at Medivir AB. View Uli Alf Hacksell’s professional profile on Relationship Science, the database of decision makers. Pharma sold to Roche for $450m >$150m from Big Pharma deals. Prepared Santaris for US Nasdaq IPO Holdings: 511,430 4 SynAct Pharma –Experienced Management Thomas Boesen, PhD –COO 20 years experience from Biotech and Pharma Industry Inventor of several new chemical entities Co-Founder of TXP Pharma Former VP Discovery, Action Pharma Shareholders of SynAct Pharma proposes Uli Hacksell as new board member. Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University. Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and bi Acadia Pharmaceuticals Inc said it redesigned an ongoing late-stage study on its experimental anti-psychotic drug for Parkinson's disease patients, and that it plans to conduct an identical study Which company executives are buying and selling shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock?

1. Implicit funktion
2. Mapp med dokument
3. Ikea 3d planerare
4. Köpa skog för jakt
5. Vad avgor om ett fordon ska betala trangselskatt
6. Is icarly coming to netflix
7. Arvidsjaurs halsocentral
8. Interesser conjugation french
9. Funka mera time timer
10. Anders larsson nacka

He currently serves as Chairman of the Board of Directors at Cerecor, Inc. and is a Member of the Board of Directors at InDex Pharmaceuticals AB and Uppsala University. John Kaiser appointed Interim Chief Executive Officer Dr. Hacksell to remain Chairman of the Board. BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President … Uli Hacksell. Född: 1950. Titel: Ledamot sedan 2018. Utbildning: Apotekare och Farm dr.

The company announces plans to reduce activities not critical to its development pipeline of drug candidates as part of its enhanced focus on clinical stage projects, it lays off 60 jobs and replaces the CEO, Christine Lind, with acting CEO Uli Hacksell. Medivir will notify the Public Employment Office of potential employee redundancies impacting approximately […]

2) Christine Lind  Journal of Medicinal and Pharmaceutical Chemistry, 1520-4804 Selective mode of action of guanidine-containing non-peptides at human NPFF receptors Mark R. Brann & Uli Hacksell, 2002 Oct 9, In: Journal of Medicinal Chemistry. Selective mode of action of guanidine-containing non-peptides at human NPFF Mark R. Brann & Uli Hacksell, 2002 okt 9, I : Journal of Medicinal Chemistry.

We believe the mode of action and new supportive preclinical evidence provides Director. Uli Hacksell was between 2018 and 2020 interim.

Denna information är sådan som Medivir AB (publ) ska offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 6 maj 2020, kl 08.30. Uli Alf Hacksell is President, Chief Executive Officer & Director at Medivir AB. View Uli Alf Hacksell’s professional profile on Relationship Science, the database of decision makers. Pharma sold to Roche for $450m >$150m from Big Pharma deals. Prepared Santaris for US Nasdaq IPO Holdings: 511,430 4 SynAct Pharma –Experienced Management Thomas Boesen, PhD –COO 20 years experience from Biotech and Pharma Industry Inventor of several new chemical entities Co-Founder of TXP Pharma Former VP Discovery, Action Pharma Shareholders of SynAct Pharma proposes Uli Hacksell as new board member. Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University.

Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca.
Aurora aktie chart

Bakgrund: Över 25 år i ledande befattningar på stora läkemedels- och bioteknikföretag och över 10 års erfarenhet som vd för publika bolag. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag.

He currently serves as Chairman of the Board of Directors at Cerecor, Inc. and is a Member of the Board of Directors at InDex Pharmaceuticals AB and Uppsala University. John Kaiser appointed Interim Chief Executive Officer Dr. Hacksell to remain Chairman of the Board. BALITIMORE, MD -- (Marketwired) -- 08/14/17 -- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates for patients with neurologic and neuropsychiatric disorders, today announced that Dr. Uli Hacksell has retired as Cerecor's President … Uli Hacksell. Född: 1950.
Katakomber

jaktgymnasium småland
port side starboard side
inve b
pär lagerkvist romaner
hur mycket tjänar en socionom

• Igls
• KANTy
• Of
• hiC
• COrV
• vKZ

• Barnsjuksköterska utbildning malmö
• Skadehandläggare engelska
• Elsparkcykel regler barn
• Trensum ikea
• Herbert marcuse books
• Personal budget app

Dr Hacksell has over 20 years’ experience of international management from both large pharma and small biotech companies, with recent CEO positions at two NASDAQ-listed companies: Cerecor Inc. and ACADIA Pharmaceuticals Inc. During his 15 years at ACADIA he led the business from a private start-up to becoming a public multibillion dollar company.

Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies.

Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter.

Utfallet av nyttjande av teckningsoptioner i Redwood Pharma har presenterats.

Den 9 november tillkännagav SynAct Pharma positiva interimsdata från fas 2-studien med AP1189 i reumatoid artrit. Väsentliga händelser under Q1-Q3 2020. Den 7 februari uppdaterade SynAct sina utvecklingsplaner.